{"organizations": [], "uuid": "28f84a03e346cc8f5c9dc3cb22d8bfe60075d2ad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regeneron-pharma-says-enter-letter/brief-regeneron-pharma-says-enter-letter-agreement-relating-to-immuno-oncology-licensecollaboration-agreement-with-sanofi-idUSFWN1P30JI", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.944, "site_type": "news", "published": "2018-01-08T20:13:00.000+02:00", "replies_count": 0, "uuid": "28f84a03e346cc8f5c9dc3cb22d8bfe60075d2ad"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regeneron-pharma-says-enter-letter/brief-regeneron-pharma-says-enter-letter-agreement-relating-to-immuno-oncology-licensecollaboration-agreement-with-sanofi-idUSFWN1P30JI", "ord_in_thread": 0, "title": "BRIEF-Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi", "locations": [], "entities": {"persons": [], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Regeneron Pharmaceuticals Inc:\n* REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​\n* REGENERON PHARMACEUTICALS-PURSUANT TO LETTER AGREEMENT, CO, SANOFI SAS, AGREED TO INCREASE REGN2810 BUDGET AMOUNT TO $1.640 BILLION\n* REGENERON -ENTERED LETTER AGREEMENT ALSO RELATING TO AMONG OTHERS​, THE INVESTOR AGREEMENT DATED AS OF JAN 11, 2014, WITH SANOFI - SEC FILING\n* REGENERON PHARMACEUTICALS INC - ‍ ALSO AGREED TO REVISE REGN2810 GLOBAL DEVELOPMENT PLAN AND REGN2810 GLOBAL DEVELOPMENT BUDGET Source text: [ bit.ly/2qIaBGi ] Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2qIaBGi"], "published": "2018-01-08T20:13:00.000+02:00", "crawled": "2018-01-09T17:09:33.004+02:00", "highlightTitle": ""}